P K Jadhav

Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors*

Chong-Hwan Chang, PatrickY.-S. Lam, P. Jadhav, 1998, The Journal of Biological Chemistry.

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

J L Meek, Chong-Hwan Chang, PatrickY.-S. Lam, 1996, Chemistry & biology.

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.

P. Jadhav, L. Bacheler, C. Chang, 1997, Journal of medicinal chemistry.

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

Chong-Hwan Chang, P. Lam, P. Jadhav, 1996, Journal of medicinal chemistry.

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.

P. Lam, P. Jadhav, C. Chang, 1998, Biochemistry.

Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.

P. Lam, P. Jadhav, Y. Ru, 1998, Journal of medicinal chemistry.

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.

J L Meek, P. Lam, P. Jadhav, 1998, Journal of medicinal chemistry.

De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule.

P K Jadhav, P Y Lam, B J Aungst, 1998, Pharmaceutical biotechnology.